Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Breast

Interventions

DRUG: Niraparib
DRUG: Placebo

Sponsor

GlaxoSmithKline